Ligand Pharmaceuticals has licensed global rights to its Captisol-enabled® topiramate injection to start-up CURx Pharmaceuticals for the treatment of partial onset or primary generalised tonic-clonic seizures in hospitalised epilepsy patients who are unable to take oral topiramate. Captisol® is drug formulation system that is designed to optimise the solubility and stability of drugs and which Ligand gained with its 2011 acquisition of CyDex Pharmaceuticals. In a Phase I clinical trial, the drug candidate demonstrated a faster onset of action than oral topiramate.